CLINICAL TRIALS PROFILE FOR NORFLEX
✉ Email this page to a colleague
All Clinical Trials for NORFLEX
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02423395 ↗ | Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With Cirrhosis | Recruiting | Tanta University | Phase 3 | 2015-01-01 | Muscle cramps are common in patients with liver disease and associated with significantly diminished quality of life. Patients with cirrhosis often experience muscle cramps with varied frequency and severity. The exact mechanisms by which they occur remain unclear, although a number of pathophysiological events unique to liver disease may contribute. Clinical studies have identified alterations in 3 areas: nerve function, energy metabolism, and plasma volume/electrolytes (1) Orphenadrine is an anticholinergic drug with prominent central nervous system (CNS) and peripheral actions used to treat painful muscle spasms and other similar conditions. The combination of anticholinergic effects and CNS penetration make orphenadrine useful for pain of all etiologies, including from: radiculopathy, muscles, and headaches. [3,4] |
| NCT02423395 ↗ | Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With Cirrhosis | Recruiting | Sherief Abd-Elsalam | Phase 3 | 2015-01-01 | Muscle cramps are common in patients with liver disease and associated with significantly diminished quality of life. Patients with cirrhosis often experience muscle cramps with varied frequency and severity. The exact mechanisms by which they occur remain unclear, although a number of pathophysiological events unique to liver disease may contribute. Clinical studies have identified alterations in 3 areas: nerve function, energy metabolism, and plasma volume/electrolytes (1) Orphenadrine is an anticholinergic drug with prominent central nervous system (CNS) and peripheral actions used to treat painful muscle spasms and other similar conditions. The combination of anticholinergic effects and CNS penetration make orphenadrine useful for pain of all etiologies, including from: radiculopathy, muscles, and headaches. [3,4] |
| NCT02449369 ↗ | Intra-Venous Acetaminophen and Muscle Relaxants After Total Knee | Completed | Sagent Pharmaceuticals Inc. | Phase 4 | 2015-04-01 | This is a prospective, three-arm, randomized, open-label trial to determine if a new pain control protocol which includes regular dosing of intravenous acetaminophen and orphenadrine for 48 hours after total knee surgery reduces the need for opioid pain medication and reduces average pain scores. |
| NCT02449369 ↗ | Intra-Venous Acetaminophen and Muscle Relaxants After Total Knee | Completed | Sagent Pharmaceuticals, Inc. | Phase 4 | 2015-04-01 | This is a prospective, three-arm, randomized, open-label trial to determine if a new pain control protocol which includes regular dosing of intravenous acetaminophen and orphenadrine for 48 hours after total knee surgery reduces the need for opioid pain medication and reduces average pain scores. |
| NCT02449369 ↗ | Intra-Venous Acetaminophen and Muscle Relaxants After Total Knee | Completed | AdventHealth | Phase 4 | 2015-04-01 | This is a prospective, three-arm, randomized, open-label trial to determine if a new pain control protocol which includes regular dosing of intravenous acetaminophen and orphenadrine for 48 hours after total knee surgery reduces the need for opioid pain medication and reduces average pain scores. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NORFLEX
Condition Name
Clinical Trial Locations for NORFLEX
Trials by Country
Clinical Trial Progress for NORFLEX
Clinical Trial Phase
Clinical Trial Sponsors for NORFLEX
Sponsor Name
